ArticleClinical drug investigation2023

Safety Concerns with Nusinersen, Risdiplam, and Onasemnogene Abeparvovec in Spinal Muscular Atrophy: A Real-World Pharmacovigilance Study.

Wei Zhuang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.